Inhibitor Therapeutics (INTI) POS AM 4 Apr 18 Prospectus update (post-effective amendment) Financial data

Document and Entity Information

Document and Entity Information	12 Months Ended
	Dec. 31, 2017
Document And Entity Information [Abstract]
Document Type	POS AM
Amendment Flag	false
Document Period End Date	Dec. 31, 2017
Trading Symbol	HPPI
Entity Registrant Name	HedgePath Pharmaceuticals, Inc.
Entity Central Index Key	1,042,418
Entity Filer Category	Smaller Reporting Company

Balance Sheets

Balance Sheets - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 344,113	$ 6,885,422
Prepaid expenses	61,655	61,097
Deposit	250,000	250,000
Total current assets	655,768	7,196,519
Other long-term assets	112,284	141,576
Total assets	768,052	7,338,095
Current liabilities:
Accounts payable	534,956	297,826
Other liabilities	66,533	10,307
Total current liabilities	601,489	308,133
Total liabilities	601,489	308,133
Commitments and contingencies
Stockholders' equity:
Preferred stock value
Common Stock, $0.0001 par value; 500,000,000 shares authorized; 369,599,266 and 353,447,172 shares issued and outstanding in 2017 and 2016, respectively	36,960	35,345
Additional paid-in capital	48,403,523	50,167,372
Accumulated deficit	(48,273,920)	(43,172,755)
Total stockholders' equity	166,563	7,029,962
Total liabilities and stockholders' equity	768,052	7,338,095
Series A Preferred Stock [Member]
Stockholders' equity:
Preferred stock value

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2017	Dec. 31, 2016
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	9,500,000	9,500,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common Stock, shares authorized	500,000,000	500,000,000
Common Stock, shares issued	369,599,266	353,447,172
Common Stock, shares outstanding	369,599,266	353,447,172
Series A Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	500,000	500,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

Statements of Operations

Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Revenues:
Total revenues	$ 0	$ 0
Expenses:
Research and development	2,227,589	2,641,507
General and administrative	2,891,442	4,380,695
Total expenses	5,119,031	7,022,202
Loss from operations	(5,119,031)	(7,022,202)
Interest income	17,866	21,985
Net loss	$ (5,101,165)	$ (7,000,217)
Basic and diluted loss per share	$ (0.01)	$ (0.02)
Weighted average common shares outstanding	366,622,107	288,752,723

Statements of Stockholders' Equ

Statements of Stockholders' Equity - USD ($)	Total	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]
Beginning balance at Dec. 31, 2015	$ 423,979	$ 24,535	$ 36,571,982	$ (36,172,538)
Beginning balance, shares at Dec. 31, 2015		245,353,270
Sale of common stock and common stock warrants	2,664,900	$ 2,712	2,662,188
Sale of common stock and common stock warrants, shares		27,115,000
Sale of common stock and common stock warrants, related party	2,788,500	$ 2,788	2,785,712
Sale of common stock and common stock warrants to related party, shares		27,885,000
Sale of warrants for cash to related party	47,924		47,924
Issuance of common stock upon warrant exercise	558,000	$ 465	557,535
Issuance of common stock upon warrant exercise, shares		4,650,000
Issuance of common stock upon warrant exercise, related party	3,983,201	$ 4,845	3,978,356
Issuance of common stock to related party upon warrant exercise, shares		48,443,902
Stock based compensation	3,563,675		3,563,675
Net loss	(7,000,217)			(7,000,217)
Ending balance at Dec. 31, 2016	7,029,962	$ 35,345	50,167,372	(43,172,755)
Ending balance, shares at Dec. 31, 2016		353,447,172
Issuance of common stock upon warrant exercise	49,500	$ 41	49,459
Issuance of common stock upon warrant exercise, shares		412,500
Issuance of common stock in payment of vested restricted stock units, net	(3,677,727)	$ 1,574	(3,679,301)
Issuance of common stock in payment of vested restricted stock units, net, shares		15,739,594
Stock based compensation	1,865,993		1,865,993
Net loss	(5,101,165)			(5,101,165)
Ending balance at Dec. 31, 2017	$ 166,563	$ 36,960	$ 48,403,523	$ (48,273,920)
Ending balance, shares at Dec. 31, 2017		369,599,266

Statements of Cash Flows

Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Operating activities:
Net loss	$ (5,101,165)	$ (7,000,217)
Adjustments to reconcile net loss to net cash flows used in operating activities:
Stock-based compensation	1,865,993	3,563,675
Changes in assets and liabilities:
Prepaid expenses and other assets	28,734	(168,259)
Accounts payable and other current liabilities	293,356	(153,747)
Net cash flows used in operating activities	(2,913,082)	(3,758,548)
Financing activities:
Proceeds from sale of common stock and common stock warrants		2,664,900
Proceeds from sale of common stock and common stock warrants, related party		2,836,424
Proceeds from exercise of common stock warrants	49,500	558,000
Proceeds from exercise of common stock warrants, related party		3,983,201
Net settlement in connection with the issuance of shares associated with underlying Restricted Stock Units	(3,677,727)
Net cash flows (used in) from financing activities	(3,628,227)	10,042,525
Net (decrease) increase in cash and cash equivalents	(6,541,309)	6,283,977
Cash and cash equivalents at beginning of year	6,885,422	601,445
Cash and cash equivalents at end of year	344,113	$ 6,885,422
Supplemental disclosure of non-cash financing activities:
Fair value of shares withheld with net settlement transaction	$ 3,677,727

Corporate overview

Corporate overview	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Corporate overview	1. Corporate overview: Overview The accompanying audited financial statements of HedgePath Pharmaceuticals, Inc., a Delaware corporation (the “Company”, “HPPI”, “we”, “us” or similar terminology) as successor to Commonwealth Biotechnologies, Inc., a Virginia corporation (“CBI”), have been prepared by the Company as a going concern, and in accordance with accounting principles generally accepted in the United States of America (“GAAP”). As used herein, the term “Common Stock” means the Company’s common stock, $0.0001 par value per share. Nature of the Business The Company is a clinical stage biopharmaceutical company that is seeking to discover, develop and commercialize innovative therapeutics for patients with certain cancers. The Company may also explore acquiring or licensing other innovative therapeutics addressing unmet needs and orphan indications beyond cancer. The Company’s preliminary focus is on the development of therapies for skin, lung and prostate cancers in the U.S. market, with the first indication targeting basal cell carcinoma in patients with Basal Cell Carcinoma Nevus Syndrome (also known as Gorlin Syndrome) for which the Company has begun dosing its Phase 2(b) clinical trial. The Company’s proposed therapy is based upon the use of SUBA-Itraconazole, which is a patented, oral formulation of the currently marketed anti-fungal drug itraconazole. The Company believes that the dosing of oral capsules of this formulation can affect the Hedgehog signaling pathway, a major regulator of many fundamental cellular processes, which, in turn, can impact the development and growth of cancers such as basal cell carcinoma. Itraconazole has been approved by the U.S. Food and Drug Administration (the “FDA”) for, and has been extensively used to, treat fungal infections and has an extensive history of safe and effective use in humans. The Company has developed, optioned and licensed intellectual property and know-how Second Amended and Restated Supply and License Agreement Pursuant to the Company’s Supply and License Agreement with Mayne Pharma Ventures Pty Ltd. and its affiliates (“Mayne Pharma”) which was originally entered into on September 3, 2013, amended and restated on June 24, 2014 and May 15, 2015, most recently amended on November 22, 2016 and January 10, 2018, Mayne Pharma is obligated to: (i) supply the Company with its patented formulation of SUBA-Itraconazole in a particular dose formulation for the treatment of human patients with cancer via oral administration (with the initial areas of investigation being prostate, lung and skin cancer) in the United States, (ii) provide the Company with an exclusive license to perform specified development activities and to commercialize SUBA-Itraconazole for the treatment of cancer via oral administration in the United States and (iii) participate in a joint development committee (the “JDC”) with the Company to clinically develop SUBA-Itraconazole for the treatment of cancer in the United States. Mayne Pharma will also provide certain services (in accordance with the development plan and budget for the Company’s product) including to direct clinical programming (subject to the oversight and approval by the JDC and, in certain circumstances, the Board of Directors), and to direct the regulatory approval process and intellectual property strategy related to the product. Any services provided to the Company by Mayne Pharma in this regard will be provided at Mayne Pharma’s expense (other than third party costs agreed to by the Company and Mayne Pharma), and such services will be subject to the Company’s prior approval. On June 24, 2014 and again on May 15, 2015, the Company and Mayne Pharma, along with Nicholas J. Virca, President and Chief Executive Officer, Frank E. O’Donnell, Jr., M.D., former Executive Chairman, and Hedgepath, LLC consummated a series of related transactions to fulfill certain conditions of the original Supply and License Agreement and Amended and Restated Supply and License Agreements, respectively. In connection therewith, the Company and Mayne Pharma entered into the Second Amended and Restated Supply and License Agreement. On November 22, 2016, the Company entered into Amendment No. 1 to the Second Amended and Restated Supply and License Agreement (the “Amendment”) with Mayne Pharma. The Amendment, which amends that certain Second Amended and Restated Supply and License Agreement, dated May 15, 2015, extends the date on which the Company must achieve regulatory approval in the U.S. to commercialize SUBA-Itraconazole to December 31, 2018 from June 30, 2017. A second amendment to the Second Amended and Restated Supply and License Agreement was entered into on January 10, 2018 and is further discussed in Note 11 below. Mayne Pharma Sublicense Agreement On September 2, 2015, the Company entered into a sublicense agreement with Mayne Pharma. Pursuant to the Agreement, Mayne Pharma sublicensed to the Company the exclusive U.S. rights to two additional patents regarding the use of Itraconazole for treatment of cancer, namely US patent No 8,980,930 entitled “Angiogenesis Inhibitors”, issued on March 17, 2015, and US patent No 8,653,083 entitled “Hedgehog Pathway Antagonists to Treat Disease”, issued on February 28, 2014. Mayne Pharma is the sublicensee of the patents from Accelas Holdings, a British Virgin Islands company, who in turn is the licensee from The Johns Hopkins University, the owner of the patents. The patents relate to the use of itraconazole as a treatment for cancer and age-related one-time May 2016 Financing On May 25, 2016, the Company conducted the final closing of its previously announced “best efforts/no minimum” private placement offering to accredited investors (the “Offering”) of the Company’s units (each a “Unit”) at a price of $0.10 per Unit, with each Unit consisting of: (i) one (1) share of the Company’s common stock, par value $0.0001 per share (“Common Stock”), and (ii) a five-year warrant to purchase one (1) share of Common Stock at an exercise price of $0.12 per share (each a “Warrant”). No actual Units were issued, and each investor received shares of Common Stock and Warrants only. During the course of the Offering, which began on March 30, 2016, the Company sold all 55,000,000 Units reserved for the Offering for aggregate gross proceeds of $5,500,000 including the units sold to Mayne Pharma as described below. The Company has granted the investors certain registration rights requiring the Company, following the Final Closing, to file a registration statement with the Securities and Exchange Commission covering the resale by the investors of the shares of Common Stock issued in the Offering and the shares of Common Stock underlying the Warrants issued in the Offering. The Company is required to use its commercially best efforts to cause the registration statement to be declared effective. The Company filed the registration statement with the Securities and Exchange Commission in June 2016, and it was declared effective on July 22, 2016. In connection with the Final Closing, and pursuant to an existing right of the Company’s license and manufacturing partner and significant stockholder Mayne Pharma to purchase its pro rata share, on a fully-diluted basis, of new securities issuances of the Company (the “Mayne Right of First Refusal”), the Company entered into a definitive Securities Purchase Agreement (“SPA”) (in substantially the same form as the SPA executed by other investors in the Offering) with Mayne Pharma, and in connection therewith issued an aggregate of 27,885,000 Units to Mayne Pharma, consisting of an aggregate of 27,885,000 shares of Common Stock and a Warrant to purchase up to an aggregate of 27,885,000 shares of Common Stock, for aggregate gross proceeds to the Company of $2,788,500. In connection with the Offering, the Company engaged certain FINRA-member agents to help it secure investors for the Offering (the “Finders Arrangements”). Such agents secured investors for an aggregate of $582,500 for the Offering and received commissions equal to an aggregate of $46,600 in cash and warrants (in substantially the form of the Warrants) to purchase 466,000 shares of Common Stock. Pursuant to the Mayne Right of First Refusal, the Company issued and sold to Mayne a warrant to purchase 479,236 shares of Common Stock for a purchase price of $47,924 (the “Mayne Finders Warrant”), which constituted Mayne’s pro rata share, on a fully-diluted basis, of all warrants issued in connection with the Finders Arrangements, inclusive of the Mayne Finders Warrant. For ease of administration, the warrant to purchase 479,236 shares of Common Stock underlying the Mayne Finders Warrant were added to the Mayne Offering Warrant, resulting in the issuance to Mayne of a single Warrant to purchase 28,364,236 shares of Common Stock. See Note 8 regarding Mayne common stock warrant exercises during the year ended December 31, 2016 and Note 11 regarding the Series B Preferred Stock Agreement with Mayne Pharma entered into in January 2018.

Liquidity and management's plan

Liquidity and management's plans	12 Months Ended
	Dec. 31, 2017
Text Block [Abstract]
Liquidity and management's plans	2. Liquidity and management’s plans: At December 31, 2017, the Company had approximately $0.3 million in cash and cash equivalents. However, in January 2018, as discussed in Note 11, the Company entered into a definitive securities purchase agreement with Mayne Pharma which guarantees at least $4.0 million in funding during 2018. Based on the Company’s current operational plan and budget, the Company expects that it has sufficient cash to manage its business into approximately the first quarter of 2019. This estimation assumes the Company does not accelerate the development of the existing product candidate, acquire other drug development opportunities, or otherwise face unexpected events, costs or contingencies, any of which could affect the Company’s cash requirements. Available resources may be consumed more rapidly than anticipated, potentially resulting in the need for additional funding.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	3. Summary of Significant Accounting Policies: Recent accounting pronouncements In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update 2014-09, In April 2016, the FASB issued ASU 2016-10, Revenue from Contracts with Customers 2016-10 In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting 2016-09 2016-09 is Management has considered all other recent accounting pronouncements that are issued, but not effective, and it does not believe that they will have a significant impact on the Company’s financial statements. Estimates The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates. Revenue Recognition The Company currently has no ongoing source of revenues. Miscellaneous income is recognized when earned by the Company. Cash and Cash Equivalents The Company considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents. At times, the Company may maintain cash balances in excess of Federal Deposit Insurance Corporation insured amounts of $250,000 for substantially all accounts. As of December 31, 2017, the Company had approximately $40,000 in excess of the amount covered by Federal Deposit Insurance Corporation with one financial institution. Research and Development Expenses Research and development costs are expensed in the period in which they are incurred and include the expenses paid to third parties who conduct research and development activities on behalf of the Company as well as purchased in-process Stock-Based Compensation The Company accounts for stock-based awards to employees and non-employees In applying the Black-Scholes options pricing model for options issued in July 2016 (see Note 8), the assumptions were as follows: expected price volatility of 113.16%; risk-free interest rate of 1.14%; weighted average expected life in years of 6; and no dividend yield. The value of these awards is based upon their grant-date fair value. That cost is recognized over the period during which the employee is required to provide service in exchange for the award. Income taxes Deferred tax assets and liabilities are recognized for future tax consequences attributed to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and are measured using enacted tax rates that are expected to apply to the differences in the periods that they are expected to reverse. See Note 7 for details. Management has evaluated the guidance relating to accounting for uncertainty in income taxes and has determined that the Company had no uncertain income tax positions that could have a significant effect on the financial statements for the years ended December 31, 2017 or 2016.

Prepaid Expenses

Prepaid Expenses	12 Months Ended
	Dec. 31, 2017
Other Income and Expenses [Abstract]
Prepaid Expenses	4. Prepaid Expenses: At December 31, 2017, prepaid expenses of $61,655 consisted primarily of approximately $42,000 of directors and officers insurance and clinical trial insurance and $20,000 in market exchange fees. At December 31, 2016, prepaid expenses of $61,097 consisted primarily of approximately $41,000 in prepaid directors and officers insurance and clinical trial insurance and $20,000 in market exchange fees.

Other Long-term Assets

Other Long-term Assets	12 Months Ended
	Dec. 31, 2017
Text Block [Abstract]
Other Long-term Assets	5. Other Long-term Assets: At December 31, 2017 and December 31, 2016, other long-term assets consisted of $112,284 and $141,576, respectively, of prepaid directors and officers insurance associated with a six-year

Other Liabilities

Other Liabilities	12 Months Ended
	Dec. 31, 2017
Other Liabilities Disclosure [Abstract]
Other Liabilities	6. Other Liabilities: At December 31, 2017, other liabilities of $66,533 consisted of accrued payroll of approximately $12,000 and accrued legal fees of approximately $55,000. At December 31, 2016, other liabilities of $10,307 consisted entirely of accrued payroll expenses.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Income Taxes	7. Income Taxes: The difference between expected income tax benefits and income tax benefit recorded in the financial statements is explained below: December 31, 2017 2016 Income taxes benefit computed at statutory rate $ (1,734,396 ) $ (2,380,073 ) State income tax benefit, net (176,082 ) (241,633 ) Change in effective tax rate 2,701,758 — Other (369,400 ) 74,355 Change in valuation allowance (421,880 ) 2,547,351 Total $ — $ — The significant components of deferred income tax assets and liabilities consist of the following: December 31, Deferred tax assets (liabilities) 2017 2016 In-process $ 736,325 $ 996,154 Net operating loss carry forward 4,759,727 2,995,024 R&D credit 211,461 142,721 Share-based compensation 9,424 2,010,742 Other 5,825 — 5,722,762 6,144,641 Less: valuation allowance (5,722,762 ) (6,144,641 ) Total $ — $ — In accordance with GAAP, it is required that a deferred tax asset be reduced by a valuation allowance if, based on the weight of available evidence it is more likely than not (a likelihood of more than 50 percent) that some portion or all of the deferred tax assets will not be realized. At December 31, 2017 and 2016, the Company recorded a 100% valuation allowance against its deferred tax assets as it has determined such amounts will not be currently realizable. The Company has a federal net operating loss (“NOLs”) of approximately $18.9 million as of December 31, 2017. Under Section 382 and 383 of the Internal Revenue Code, if an ownership change occurs with respect to a “loss corporation”, as defined, there are annual limitations on the amount of the NOLs and other deductions which are available to the Company. The portion of the NOLs incurred prior to August 12, 2013 is subject to this limitation. As such, the use of these NOLs to offset taxable income is limited to approximately $35,000 per year and the Company has written off the deferred tax assets associated with the NOLs limited due to the ownership change that occurred on August 12, 2013. The Company’s State NOLS are approximately $18.9 million as of December 31, 2017. The loss carryforwards begin to expire in 2018.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2017
Equity [Abstract]
Stockholders' Equity	8. Stockholders’ Equity: Employee Stock Plans A 2009 Stock Incentive Plan was adopted by the Board of Directors and approved by the shareholders of CBI. There are no options outstanding under this plan. On July 18, 2014, the EIP was adopted by the Company’s Board of Directors. On September 30, 2014, the EIP was approved by the majority of stockholders. The 2014 EIP authorizes the issuance of up to 32,583,475 shares of the Company’s common stock. In July 2014, 15,041,738 restricted stock units (“RSUs”) were granted to the Company’s Chief Executive Officer, Nicholas J. Virca, and were to vest upon the earlier to occur of (i) September 3, 2016 or (ii) the acceptance by the FDA of a New Drug Application (“NDA”) by the Company for any Company product candidate with a cancer indication utilizing the Company’s licensed SUBA-itraconazole technology, provided that Mr. Virca is actively employed by the Company on the earlier of such date. An additional 1.5 million RSUs were issued to various Board members and officers with the same vesting schedule. In August 2014, 7,000,000 RSUs were issued to the Company’s Chief Financial Officer, Garrison J. Hasara. Of those RSUs, 50% were to vest upon the earlier to occur of (i) September 3, 2016 or (ii) the acceptance by the FDA of a NDA by the Company for any Company product candidate with a cancer indication utilizing the Company’s licensed SUBA-itraconazole technology, provided that Mr. Hasara is actively employed by the Company on the earlier of such date. Mr. Hasara’s balance of RSUs were to vest September 3, 2017. As discussed below, all RSU’s mentioned above vested in November 2016 upon a change in control. In August 2015, the Company issued a total of 2,350,000 RSUs to various members the Board of Directors and management of the Company. Of this amount, the 750,000 RSUs issued to management were to vest over three years. The 1,600,000 issued to Board members were to vest the earlier of September 5, 2017 and FDA approval of an NDA for any product candidate with a cancer indication utilizing the Company’s licensed SUBA-itraconazole technology. There were 125,000 outstanding RSUs at December 31, 2017, all of which were issued in May 2017 to recently added Board members. All of the outstanding RSUs at December 31, 2017 vested on January 1, 2018. These RSUs were issued pursuant to the Plan. On July 1, 2016, the three independent members of the Board of Directors and the Secretary received a total grant of 650,000 RSUs and 650,000 common stock options with an exercise price of $0.24 per share. Stock option activity for the year ended December 31, 2016 and 2017 is as follows: Number of Weighted Aggregate Outstanding at January 1, 2016 — n/a n/a Granted to Directors and Officers in 2016 650,000 $ 0.24 Exercised — — Forfeitures — — Outstanding at December 31, 2016 650,000 $ 0.24 $ 97,500 No activity in 2017 — — Outstanding at December 31, 2017 650,000 $ 0.24 $ 6,500 In November 2016, pursuant to the change in control provision in the EIP, all then outstanding RSUs and stock options vested when Mayne Pharma exercised Common Stock warrants and exceeded 50% ownership the of outstanding Common Stock. The RSU shares were issued on March 8, 2017, net of 10,802,144 shares of Common Stock which were withheld from issuance representing estimated income taxes due from the vested RSUs. No stock options have been exercised as of December 31, 2017. Going forward, incentive awards may be in the form of stock options, restricted stock, restricted stock units and performance and other awards. In the case of incentive stock options, the exercise price will not be less than 100% of the fair market value of shares covered at the time of the grant, or 110% for incentive stock options granted to persons who own more than 10% of the Company’s voting stock. Options granted will generally vest over a three-year period from the date of grant and will be exercisable for ten years, except that the term may not exceed five years for incentive stock options granted to persons who own more than 10% of the Company’s outstanding common stock. Stock-based compensation expense is determined based on the fair value of the stock-based awards and recognized over the vesting period. The Company recognized $1,865,993 and $3,563,675 in stock-based compensation expense related to Restricted Stock Units and stock options for the years ended December 31, 2017 and 2016, respectively. As of December 31, 2017, there was no unamortized stock-based compensation. Common Stock Issuances See Note 1 for discussion of Common Stock issued in conjunction with the Mayne Pharma Purchase Agreement and the May 2016 Financing. Preferred Stock Issuances See Note 11 for discussion of Preferred stock issued to Mayne Pharma subsequent to December 31, 2017. Warrants See Note 1 for discussion of warrants issued in conjunction with the Mayne Pharma Purchase Agreement and the May 2016 Financing. See Note 11 for discussion of the warrants in connection with the Series B Preferred Stock Purchase Agreement. Details of the 2016 and 2017 warrant exercises can be found in the chart below: Year Warrant Holder # of Exercise Total Proceeds 2016 Mayne 10,250,569 $ 0.0878 $ 900,000 2016 Mayne 33,333,333 $ 0.075 2,500,001 2016 Mayne 4,860,000 $ 0.12 583,200 Total Mayne exercises 48,443,902 3,983,201 2016 May 2016 Financing Finders 150,000 $ 0.12 18,000 2016 May 2016 Financing Investors 4,500,000 $ 0.12 540,000 Total common stock warrant exercises for the twelve months ended December 31, 2016 53,093,902 $ 4,541,201 2017 May 2016 Financing Investors 412,500 $ 0.12 $ 49,500 Total common stock warrant exercises for the twelve months ended December 31, 2017 412,500 $ 49,500 There were 56,273,305 outstanding common stock warrants at December 31, 2017 with a weighted average exercise price of $0.11 and a weighted average remaining life of 3.0 years.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2017
Related Party Transactions [Abstract]
Related Party Transactions	9. Related party transactions: The Company has significant contractual agreements with majority stockholder Mayne Pharma as discussed in Note 1 and Note 11. There were no amounts due to or from Mayne Pharma at December 31, 2017, other than the amount due in 2018 to the Company from Mayne Pharma under the Series B Preferred Stock Purchase Agreement as discussed in Note 11.

Legal Proceedings

Legal Proceedings	12 Months Ended
	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Legal Proceedings	10. Legal Proceedings: The Company is currently not subject to any material legal proceedings. However, the Company may from time to time become a party to various legal proceedings arising in the ordinary course of business.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2017
Subsequent Events [Abstract]
Subsequent Events	11. Subsequent Events: Series B Preferred Stock Purchase Agreement On January 8, 2018, the Company entered into a definitive securities purchase agreement (the “Purchase Agreement”) with Mayne Pharma, pursuant to which Mayne Pharma agreed to purchase from the Company, and the Company agreed to issue to Mayne Pharma (over three closings as described further below, each a “Closing”): (i) up to 7,246,377 shares of the Company’s newly designed Series B Convertible Preferred Stock (the “Series B Preferred Stock”) at $0.69 per share of Series B Preferred Stock (with each share of Series B Preferred Stock being convertible into three (3) shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), for an effective price per share of Common Stock of $0.23), for potential gross proceeds of $5,000,000; (ii) Series A warrants (the “Series A Warrants”) to purchase up to an aggregate 5,434,783 shares of Common Stock, with a two-year (iii) Series B warrants (the “Series B Warrants”) to purchase up to an aggregate of 5,434,783 shares of Common Stock, with a five-year term from the date of issuance and an exercise price per share of $0.275 (the “Series B Warrants”, and together with the Series A Warrants, the “Warrants”). The transactions contemplated by the Purchase Agreement are referred to herein as the “Financing.” The Financing contemplates three closings (each, a “Closing”), as follows: (i) $2.4 million was funded at an initial closing of the Financing that occurred on January 10, 2018 (the “Initial Closing”); (ii) $1.6 million shall be funded on or before July 1, 2018 (the “Second Closing”); and (iii) $1.0 million may be funded on or before December 31, 2018 (the “Third Closing”). There are no operational milestones of the Company associated with Mayne Pharma’s obligation to purchase the shares of Series B Preferred Stock and Warrants at the Second Closing, which shall only be subject to customary closing conditions. The funding of the Third Closing shall be conditioned upon the acceptance of filing by the U.S. Food and Drug Administration (the “FDA”) of the Company’s New Drug Application (“NDA”) for SUBA-Itraconazole for the treatment of Basal Cell Carcinoma Nevus Syndrome (“SUBA BCCNS”), provided that such date shall be automatically extended in the event that such NDA is filed with the FDA during December 2018 to a date which is 30 days from the date of such filing. In addition, as part of the Financing, the Company and Mayne Pharma agreed to amend certain provisions of the Second Amended and Restated Supply and License Agreement, dated as of May 15, 2016, between the Company and Mayne Pharma, as amended by that Amendment No. 1 thereto, effective as of November 22, 2016 (collectively, the “Supply and License Agreement”), most notably to eliminate the provision that would have allowed Mayne Pharma to terminate the Supply and License Agreement in the event that the Company had not received an NDA approval for a product covered by the Supply and License Agreement by October 31, 2018. Under the Purchase Agreement, the Company has agreed to use the proceeds from the Financing solely for purposes of funding the continued development of SUBA BCCNS and for general corporate purposes; provided, however, that the Company may use the proceeds from the Third Closing (in a manner consistent with the Supply and License Agreement) for the development of other SUBA-Itraconazole treatments for cancer and for general operating purposes of the Company. In addition, the Purchase Agreement provides for additional limitations on the use of proceeds from the Financing including, without limitation, that the Company shall not use the proceeds from any Closing for: (i) the satisfaction of any portion of the Company’s indebtedness (other than payment of trade payables in the ordinary course of the Company’s business and prior practices) or (ii) the redemption of any Common Stock or other Company securities. In addition, under the Purchase Agreement, the Company agreed that for the period from the date of the Initial Closing through December 31, 2018 (the “Market Standoff Period”), the Company will not undertake external financing (which shall specifically exclude exercise of existing options and warrants) without the approval of Mayne Pharma, such approval not to be unreasonably withheld, conditioned or delayed, and giving due consideration to the fiduciary duties and business judgment of the Company’s Board of Directors; provided, however, that if, during the Market Standoff Period, any existing warrants or options of the Company are exercised, the proceeds of such exercises may, in the discretion of the Company’s Board of Directors, be used for preliminary work on SUBA-Itraconazole cancer indications other than SUBA BCCNS, in each case in accordance with the Supply and License Agreement. Under the Purchase Agreement, Mayne Pharma has been afforded certain demand and “piggyback” rights to cause the Company to register the shares of Common Stock underlying the Series B Preferred Stock and the Warrants for public resale; provided, however, that such rights shall only become effective and exercisable from and after the termination of the Supply and License Agreement. The negotiations with Mayne Pharma and preparation of related transaction documentation associated with Financing and amendment to the Supply and License Agreement was undertaken on behalf of the Company by a special committee of disinterested, independent members of the Company’s Board of Directors. Terms of the Series B Preferred Stock The Series B Preferred Stock carries the following provisions: Price Per Share Dividends 6-month Voluntary and Mandatory Conversion Liquidation Preference Seniority Voting Redemption Terms of the Warrants The Warrants are divided equally between the Series A Warrants and the Series B Warrants (i.e., with each being exercisable for an aggregate of 5,434,783 shares of Common Stock if all Closings occur), which represents fifty percent (50%) warrant coverage on the shares of Common Stock underlying the Series B Preferred Stock. The Warrants will be issued, pro rata in relation to the total investment in the Series B Preferred Stock, at each Closing. The Warrants are substantially identical in form, except that: (i) the exercise price per share of the Series A Warrants shall be $0.23 per share and the exercise price per share of the Series B Warrants shall be $0.275 per share (collectively, the “Warrant Exercise Price”) and (ii) The Series A Warrants shall have a term of two (2) years from the date of issuance and the Series B Warrants shall have term of five (5) years from the date of issuance. The Warrant Exercise Price shall be subject to customary stock-based, but not price-based, anti-dilution protection. The Warrants will not be eligible for “cashless” exercise. Amendment to Supply and License Agreement In connection with the Initial Closing, on January 10, 2018, the Company and Mayne Pharma entered into an amendment to the Supply and License Agreement (the “SLA Amendment”) to eliminate Mayne Pharma’s right to terminate the Supply and License Agreement if the Company fails to secure NDA approval for a SUBA-Itraconazole-based 60-day Mayne Pharma’s election to trigger the Mayne BCCNS Assumption Right shall not terminate the Supply and License Agreement or impact the Company’s ability to pursue other product development opportunities under and in accordance with the terms of the Supply and License Agreement. The Company BCCNS License includes: (i) a cash royalty to the Company from Mayne Pharma on all net sales of SUBA BCCNS in the United States, (ii) the forfeiture by Mayne Pharma under the Sublicense Agreement (as defined below) of (x) royalties from the Company with respect to SUBA BCCNS sales and (y) a portion of the milestone payments due by the Company to Mayne Pharma under the Sublicense Agreement and (iii) indemnification of the Company by Mayne Pharma for any claims incurred by the Company arising out of Mayne Pharma’s SUBA BCCNS activities following the exercise of the Mayne BCCNS Assumption Right. The term “Target Failure” means if: (i) the FDA has not accepted for filing the Company’s NDA for SUBA BCCNS by December 31, 2018, provided that such date shall be automatically extended in the event that such NDA is filed with the FDA during December 2018 to a date which is 30 days from the date of such filing or (ii) the commercial launch of SUBA BCCNS is not achieved by June 30, 2020. The SLA Amendment also amends corresponding provisions of that certain Sublicense Agreement, dated August 31, 2015, between Mayne Pharma International Pty Ltd, an affiliate of Mayne Pharma (“Mayne Pharma International”), and the Company, in order to conform to the business terms agreed to in the SLA Amendment. The Certificate of Designation of the Series B Preferred Stock (as corrected pursuant to a Certificate of Correction), the Purchase Agreement, the form of Warrants and the SLA Amendment are attached to this Current Report as Exhibits 3.1, 10.1, 4.1 and 10.2, respectively. All descriptions of such documents are qualified in their entirety to the full text of Exhibits 3.1, 3.2, 10.1, 4.1 and 10.2 hereto, which is incorporated herein by reference. The securities issued at the Initial Closing above have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), and sales were made pursuant to the exemptions from registration provided by Section 4(a)(2) of the Securities Act and/or Rule 506(b) of Regulation D (“Reg. D”) promulgated under the Securities Act because, among other things, Mayne Pharma is an “accredited investor” (as defined under Reg. D) and Mayne Pharma purchased the securities for its own account and not with a view to distributing or reselling the securities in violation of the Securities Act. Pro Forma Balance Sheet If the Purchase Agreement had been entered into on December 31, 2017, the Company’s balance sheet would have reflected a cash balance of $2,744,113, total assets of $3,168,052 and total stockholders’ equity of $2,566,563.

Summary of Significant Accoun18

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Recent accounting pronouncements	Recent accounting pronouncements In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update 2014-09, In April 2016, the FASB issued ASU 2016-10, Revenue from Contracts with Customers 2016-10 In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting 2016-09 2016-09 is Management has considered all other recent accounting pronouncements that are issued, but not effective, and it does not believe that they will have a significant impact on the Company’s financial statements.
Estimates	Estimates The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.
Revenue Recognition	Revenue Recognition The Company currently has no ongoing source of revenues. Miscellaneous income is recognized when earned by the Company.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents. At times, the Company may maintain cash balances in excess of Federal Deposit Insurance Corporation insured amounts of $250,000 for substantially all accounts. As of December 31, 2017, the Company had approximately $40,000 in excess of the amount covered by Federal Deposit Insurance Corporation with one financial institution.
Research and Development Expenses	Research and Development Expenses Research and development costs are expensed in the period in which they are incurred and include the expenses paid to third parties who conduct research and development activities on behalf of the Company as well as purchased in-process
Stock-Based Compensation	Stock-Based Compensation The Company accounts for stock-based awards to employees and non-employees In applying the Black-Scholes options pricing model for options issued in July 2016 (see Note 8), the assumptions were as follows: expected price volatility of 113.16%; risk-free interest rate of 1.14%; weighted average expected life in years of 6; and no dividend yield. The value of these awards is based upon their grant-date fair value. That cost is recognized over the period during which the employee is required to provide service in exchange for the award.
Income taxes	Income taxes Deferred tax assets and liabilities are recognized for future tax consequences attributed to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and are measured using enacted tax rates that are expected to apply to the differences in the periods that they are expected to reverse. See Note 7 for details. Management has evaluated the guidance relating to accounting for uncertainty in income taxes and has determined that the Company had no uncertain income tax positions that could have a significant effect on the financial statements for the years ended December 31, 2017 or 2016.

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Difference Between Expected Income Tax Benefits and Income Tax Benefit Recorded in the Financial Statements	The difference between expected income tax benefits and income tax benefit recorded in the financial statements is explained below: December 31, 2017 2016 Income taxes benefit computed at statutory rate $ (1,734,396 ) $ (2,380,073 ) State income tax benefit, net (176,082 ) (241,633 ) Change in effective tax rate 2,701,758 — Other (369,400 ) 74,355 Change in valuation allowance (421,880 ) 2,547,351 Total $ — $ —
Components of Deferred Income Tax Assets and Liabilities	The significant components of deferred income tax assets and liabilities consist of the following: December 31, Deferred tax assets (liabilities) 2017 2016 In-process $ 736,325 $ 996,154 Net operating loss carry forward 4,759,727 2,995,024 R&D credit 211,461 142,721 Share-based compensation 9,424 2,010,742 Other 5,825 — 5,722,762 6,144,641 Less: valuation allowance (5,722,762 ) (6,144,641 ) Total $ — $ —

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2017
Equity [Abstract]
Schedule of Stock Option Activity	Stock option activity for the year ended December 31, 2016 and 2017 is as follows: Number of Weighted Aggregate Outstanding at January 1, 2016 — n/a n/a Granted to Directors and Officers in 2016 650,000 $ 0.24 Exercised — — Forfeitures — — Outstanding at December 31, 2016 650,000 $ 0.24 $ 97,500 No activity in 2017 — — Outstanding at December 31, 2017 650,000 $ 0.24 $ 6,500
Summary of Warrant Exercises	Details of the 2016 and 2017 warrant exercises can be found in the chart below: Year Warrant Holder # of Exercise Total Proceeds 2016 Mayne 10,250,569 $ 0.0878 $ 900,000 2016 Mayne 33,333,333 $ 0.075 2,500,001 2016 Mayne 4,860,000 $ 0.12 583,200 Total Mayne exercises 48,443,902 3,983,201 2016 May 2016 Financing Finders 150,000 $ 0.12 18,000 2016 May 2016 Financing Investors 4,500,000 $ 0.12 540,000 Total common stock warrant exercises for the twelve months ended December 31, 2016 53,093,902 $ 4,541,201 2017 May 2016 Financing Investors 412,500 $ 0.12 $ 49,500 Total common stock warrant exercises for the twelve months ended December 31, 2017 412,500 $ 49,500

Corporate Overview - Additional

Corporate Overview - Additional Information (Detail)	May 25, 2016USD ($)$ / sharesshares	Dec. 31, 2017USD ($)$ / sharesshares	Dec. 31, 2016USD ($)$ / shares	Sep. 02, 2015Patents
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Common stock, par value | $ / shares		$ 0.0001	$ 0.0001
Sale of common stock and common stock warrants, related party | $			$ 2,664,900
Finders Arrangements [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Sale of common stock and common stock warrants, related party | $		$ 582,500
Sale of common stock and common stock warrants to related party, shares		466,000
Commission paid to agents | $		$ 46,600
Mayne Pharma Ventures Pty LTD [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Warrants issued to purchase common stock		28,364,236
Mayne Pharma Ventures Pty LTD [Member] | Securities Purchase Agreement [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Sale of common stock and common stock warrants, related party | $		$ 2,788,500
Sale of common stock and common stock warrants to related party, shares		27,885,000
Aggregate number of common stock and warrants issued		27,885,000
Warrants issued to purchase common stock		27,885,000
Mayne Pharma Ventures Pty LTD [Member] | Finders Arrangements [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Sale of common stock and common stock warrants, related party | $		$ 47,924
Warrants issued to purchase common stock		479,236
Accredited Investor [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Common stock, par value | $ / shares	$ 0.0001
Shares issued, price per share | $ / shares	$ 0.10
Number of securities into which each warrant or right converted	1
Number of securities into which the class of warrant or right converted	1
Warrant expiration period	5 years
Exercise price of warrants | $ / shares	$ 0.12
Private Placement [Member] | Accredited Investor [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Sale of common stock and common stock warrants, related party | $	$ 5,500,000
Sale of common stock and common stock warrants to related party, shares	55,000,000
Mayne Pharma [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
License fee paid | $		$ 75,000
Number of patents sublicensed | Patents				2

Liquidity and Management's Pl22

Liquidity and Management's Plans - Additional Information (Detail) - USD ($)	Jan. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Bankruptcy [Line Items]
Cash and cash equivalents		$ 344,113	$ 6,885,422	$ 601,445
Mayne Pharma Ventures Pty LTD [Member] | Securities Purchase Agreement [Member] | Subsequent Event [Member]
Bankruptcy [Line Items]
Guaranteed funding receivable	$ 4,000,000

Summary of Significant Accoun23

Summary of Significant Accounting Policies - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2017USD ($)
Accounting Policies [Line Items]
Cash, FDIC insured amount	$ 250,000
Cash balance in excess of amount covered by Federal Deposit Insurance Corporation	$ 40,000
Black-Scholes Option Pricing Model [Member]
Accounting Policies [Line Items]
Volatility rate	113.16%
Risk-free interest rate	1.14%
Weighted average expected life (in years)	6 years
Dividend yield	0.00%

Prepaid Expenses - Additional I

Prepaid Expenses - Additional Information (Detail) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Disclosure Prepaid Expenses And Other Assets Details [Line Items]
Prepaid expenses	$ 61,655	$ 61,097
Directors and Officers [Member] | Clinical Trial Insurance [Member]
Disclosure Prepaid Expenses And Other Assets Details [Line Items]
Prepaid expenses	42,000	41,000
Directors and Officers [Member] | Market Exchange Fees [Member]
Disclosure Prepaid Expenses And Other Assets Details [Line Items]
Prepaid expenses	$ 20,000	$ 20,000

Other Long-term Assets - Additi

Other Long-term Assets - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Other Assets, Noncurrent [Abstract]
Other long-term assets	$ 112,284	$ 141,576
Term of insurance policy, tail coverage	6 years

Other Liabilities - Additional

Other Liabilities - Additional Information (Detail) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Other Liabilities [Line Items]
Other liabilities	$ 66,533	$ 10,307
Other Liabilities [Member]
Other Liabilities [Line Items]
Accrued payroll expenses	12,000	$ 10,307
Accrued legal expenses	$ 55,000

Income Taxes - Difference Betwe

Income Taxes - Difference Between Expected Income Tax Benefits and Income Tax Benefit Recorded in the Financial Statements (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Income taxes benefit computed at statutory rate	$ (1,734,396)	$ (2,380,073)
State income tax benefit, net	(176,082)	(241,633)
Change in effective tax rate	2,701,758
Other	(369,400)	74,355
Change in valuation allowance	(421,880)	2,547,351
Expected income tax benefits and income tax benefits recorded	$ 0	$ 0

Income Taxes - Components of De

Income Taxes - Components of Deferred Income Tax Assets and Liabilities (Detail) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Income Tax Disclosure [Abstract]
In-process research and development	$ 736,325	$ 996,154
Net operating loss carry forward	4,759,727	2,995,024
R&D credit	211,461	142,721
Share-based compensation	9,424	2,010,742
Other	5,825
Deferred tax assets gross	5,722,762	6,144,641
Less: valuation allowance	(5,722,762)	(6,144,641)
Deferred tax assets, net	$ 0	$ 0

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Income Taxes [Line Items]
Percentage of valuation allowance against deferred tax assets	100.00%	100.00%
Valuation Allowance, Methodologies and Assumptions	In accordance with GAAP, it is required that a deferred tax asset be reduced by a valuation allowance if, based on the weight of available evidence it is more likely than not (a likelihood of more than 50 percent) that some portion or all of the deferred tax assets will not be realized.
NOLs used to offset taxable income	$ 35,000
Minimum [Member]
Income Taxes [Line Items]
Valuation Allowance, Assumption Percentage	50.00%	50.00%
Domestic Tax Authority [Member]
Income Taxes [Line Items]
Net operating loss carryforward	$ 18,900,000
State and Local Jurisdiction [Member]
Income Taxes [Line Items]
Net operating loss carryforward	$ 18,900,000
Operating loss carryforward expiration period	Dec. 31, 2017

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($)	Mar. 08, 2017	Jul. 01, 2016	Aug. 31, 2015	Aug. 31, 2014	Dec. 31, 2017	Dec. 31, 2016	Jan. 01, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Option outstanding under 2009 stock incentive plan					650,000	650,000
Stock options exercised					0	0
Total stock based compensation expense related to Restricted Stock Units and stock options					$ 1,865,993	$ 3,563,675
Number of outstanding common stock warrants					56,273,305
Weighted average exercise price of outstanding common stock warrants					$ 0.11
Weighted average remaining life of outstanding common stock warrants					3 years
Directors and Officers [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options granted during the period						650,000
Stock options exercise price						$ 0.24
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
RSUs issued to Chief Financial Officer			1,600,000
Options granted vesting period			3 years
Non equity instruments outstanding					125,000
Common Stock withheld from issuance representing estimated income taxes due from vested RSUs	10,802,144
Total stock based compensation expense related to Restricted Stock Units and stock options					$ 1,865,993	$ 3,563,675
Unamortized stock-based compensation cost related to unpaid RSUs					$ 0
Restricted Stock Units (RSUs) [Member] | CEO [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
RSUs issued to Chief Financial Officer				7,000,000
RSUs vesting percentage				50.00%
Restricted Stock Units (RSUs) [Member] | Board of Directors and Management [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
RSUs issued to Chief Financial Officer			2,350,000
Restricted Stock Units (RSUs) [Member] | Management [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
RSUs issued to Chief Financial Officer			750,000
Restricted Stock Units (RSUs) [Member] | Board Members, Company Secretary and Chief Compliance Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock units granted during the period		650,000
Stock options granted during the period		650,000
Stock options exercise price		$ 0.24
Restricted Stock Units (RSUs) [Member] | Subsequent Event [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Non equity instruments vested							125,000
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted vesting period					3 years
Period during which options are exercisable					10 years
Employee Stock Option [Member] | More Than 10% Common Stock Owners [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price as percentage of fair market value of shares					110.00%
Minimum percentage of the company's voting stock ownership for 110% exercise price of stock options					10.00%
Employee Stock Option [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price as percentage of fair market value of shares					100.00%
Employee Stock Option [Member] | Maximum [Member] | More Than 10% Common Stock Owners [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Period during which options are exercisable					5 years
2009 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Option outstanding under 2009 stock incentive plan					0
Equity Incentive Plan [Member] | 2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized to be issued under Equity Incentive Plan					32,583,475
Equity Incentive Plan [Member] | Restricted Stock Units (RSUs) [Member] | 2014 [Member] | CEO [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock units granted during the period					15,041,738
Equity Incentive Plan [Member] | Restricted Stock Units (RSUs) [Member] | 2014 [Member] | Directors and Officers [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock units granted during the period					1,500,000

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Stock Option Activity (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding, Beginning Balance	650,000
Number of Shares, Exercised	0	0
Number of Shares, Forfeitures		0
Number of Shares, Outstanding, Ending Balance	650,000	650,000
Weighted Average Exercise Price per Share, Exercised		$ 0
Weighted Average Exercise Price per Share, Forfeitures		0
Weighted Average Exercise Price per Share, Outstanding, Ending Balance	$ 0.24	$ 0.24
Aggregate Intrinsic Value, Exercised		$ 0
Aggregate Intrinsic Value, Forfeitures		0
Aggregate Intrinsic Value, Ending Balance	$ 6,500	$ 97,500
Aggregate Intrinsic Value, Granted	$ 0
Directors and Officers [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Granted		650,000
Weighted Average Exercise Price per Share, Granted		$ 0.24
Aggregate Intrinsic Value, Granted		$ 0

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Warrant Exercises (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Class of Warrant or Right [Line Items]
Total Proceeds	$ 49,500	$ 558,000
Mayne [Member]
Class of Warrant or Right [Line Items]
Number of Warrants		10,250,569
Exercise Price		$ 0.0878
Total Proceeds		$ 900,000
Mayne [Member]
Class of Warrant or Right [Line Items]
Number of Warrants		33,333,333
Exercise Price		$ 0.0750
Total Proceeds		$ 2,500,001
Mayne [Member]
Class of Warrant or Right [Line Items]
Number of Warrants		4,860,000
Exercise Price		$ 0.1200
Total Proceeds		$ 583,200
Total Mayne Exercises [Member]
Class of Warrant or Right [Line Items]
Number of Warrants		48,443,902
Total Proceeds		$ 3,983,201
May 2016 Financing Finders [Member]
Class of Warrant or Right [Line Items]
Number of Warrants		150,000
Exercise Price		$ 0.1200
Total Proceeds		$ 18,000
May 2016 Financing Investors [Member]
Class of Warrant or Right [Line Items]
Number of Warrants		4,500,000
Exercise Price		$ 0.1200
Total Proceeds		$ 540,000
Mayne and May 2016 [Member]
Class of Warrant or Right [Line Items]
Number of Warrants		53,093,902
Total Proceeds		$ 4,541,201
May 2017 Financing Investors [Member]
Class of Warrant or Right [Line Items]
Number of Warrants	412,500
Exercise Price	$ 0.1200
Total Proceeds	$ 49,500
May 2017 Financing Investors [Member]
Class of Warrant or Right [Line Items]
Number of Warrants	412,500
Total Proceeds	$ 49,500

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - Mayne Pharma [Member]	Dec. 31, 2017USD ($)
Related Party Transaction [Line Items]
Due to Mayne Pharma	$ 0
Due from Mayne Pharma	$ 0

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail)	Dec. 31, 2018USD ($)	Jul. 01, 2018USD ($)	Jan. 10, 2018USD ($)	Jan. 08, 2018USD ($)ClosingsMilestone$ / sharesshares	Dec. 31, 2017USD ($)$ / shares	Dec. 31, 2016USD ($)$ / shares	Dec. 31, 2015USD ($)
Subsequent Event [Line Items]
Common stock par value | $ / shares					$ 0.0001	$ 0.0001
Cash balance					$ 344,113	$ 6,885,422	$ 601,445
Total assets					768,052	7,338,095
Total stockholders' equity					166,563	7,029,962	423,979
Common Stock [Member]
Subsequent Event [Line Items]
Total stockholders' equity					36,960	$ 35,345	$ 24,535
Securities Purchase Agreement [Member] | Pro Forma [Member]
Subsequent Event [Line Items]
Cash balance					2,744,113
Total assets					3,168,052
Total stockholders' equity					$ 2,566,563
Mayne Pharma [Member] | Securities Purchase Agreement [Member] | Second Closing [Member] | Scenario, Forecast [Member]
Subsequent Event [Line Items]
Purchase Agreement, potential gross proceeds		$ 1,600,000
Mayne Pharma [Member] | Securities Purchase Agreement [Member] | Third Closing [Member] | Scenario, Forecast [Member]
Subsequent Event [Line Items]
Purchase Agreement, potential gross proceeds	$ 1,000,000
Subsequent Event [Member] | Mayne Pharma [Member]
Subsequent Event [Line Items]
Number of operational milestones | Milestone				0
Subsequent Event [Member] | Mayne Pharma [Member] | Securities Purchase Agreement [Member]
Subsequent Event [Line Items]
Common stock par value | $ / shares				$ 0.0001
Purchase Agreement, potential gross proceeds				$ 5,000,000
Number of closings | Closings				3
Percentage of warrant coverage on shares of Common Stock				50.00%
Subsequent Event [Member] | Mayne Pharma [Member] | Securities Purchase Agreement [Member] | Common Stock [Member]
Subsequent Event [Line Items]
Purchase Agreement, price per share of preferred stock to be issued | $ / shares				$ 0.23
Subsequent Event [Member] | Mayne Pharma [Member] | Securities Purchase Agreement [Member] | Series A Warrants [Member]
Subsequent Event [Line Items]
Warrants issued to purchase common stock | shares				5,434,783
Warrant expiration period				2 years
Exercise price of warrants | $ / shares				$ 0.23
Subsequent Event [Member] | Mayne Pharma [Member] | Securities Purchase Agreement [Member] | Series B Warrants [Member]
Subsequent Event [Line Items]
Warrants issued to purchase common stock | shares				5,434,783
Warrant expiration period				5 years
Exercise price of warrants | $ / shares				$ 0.275
Subsequent Event [Member] | Mayne Pharma [Member] | Securities Purchase Agreement [Member] | Series B Preferred Stock [Member]
Subsequent Event [Line Items]
Purchase Agreement, preferred stock to be issued | shares				7,246,377
Purchase Agreement, price per share of preferred stock to be issued | $ / shares				$ 0.69
Purchase Agreement, number of common stock issued upon conversion of a preferred stock				3
Preferred stock dividend rate percentage				5.00%
Dividends payable nature				Dividends will be paid semi-annually as of June 30 (with a payment date of July 15) and December 31 (with a payment date of January 15) each year. The Company shall have the option in its discretion to pay dividends in cash or shares of Common Stock. If the Company elects to pay dividends in shares of Common Stock, the number of shares to be paid being calculated by dividing (i) the principal value of the dividend to be paid by (ii) the 6-month volume-weighted average price of the Common Stock prior to the measurement date (being 31 December, or 30 June) of the applicable year.
Preferred stock convertible to common stock | shares				21,739,131
Subsequent Event [Member] | Mayne Pharma [Member] | Securities Purchase Agreement [Member] | Series B Preferred Stock [Member] | Minimum [Member]
Subsequent Event [Line Items]
Purchase Agreement, redemption period				5 years
Subsequent Event [Member] | Mayne Pharma [Member] | Securities Purchase Agreement [Member] | Initial Closing [Member]
Subsequent Event [Line Items]
Purchase Agreement, gross proceeds			$ 2,400,000